When Science Finds Its Soul — The Founder Who Dared to Dream Beyond Limits
In the unforgiving realm of oncology, where therapies can be just as vicious as cancer, Pallando Therapeutics was found in 2024 under the leadership of Miro Brajenovic. With decades of experience in biotech and global health, it’s not just cancer itself that Branjenovic knows well, but also the suffering that patients experience, and the financial, emotional, and physical burdens that conventional therapies can bring.
He wasn’t out pursuing headline making discoveries; he was out pursuing a new vision of cancer care: practical, affordable, and kind. And Pallando was born- a company where medicine is not just engineered in labs, but engineered for lives.
Rethinking the Battle — Innovation That Heals Without Harm
Most cancer drugs reside at two extremes: costly precision medicines developed in recent years that only a fraction of patients can access, or older drugs that have lost their patent protection without being replaced with innovation that can address today’s cancers.
Pallando Therapeutics is at the crossroads, with next generation oncology that meld leading edge science and reachability.
The work they are exploring involves precision targeted therapies, or treatments that attack cancer cells specifically, thereby minimising side effects and enhancing the quality of life for patients. But the distinction is not only scientific; it is also moral. Pallando is patient centric, and makes innovation unlocked from price tags or patents.
Pallando is more than a biotech company; it’s a steward of hope.
Read Also: Kasa: Redefining Hospitality Through Technology, Comfort, and Human Connection
Breaking Barriers of Access — Where Discovery Meets Delivery
For Pallando, success isn’t when treatments receive FDA approvals, but when they actually reach the patients who need them.
In its first year, Pallando has progressed several preclinical candidates, filed patents, and set up collaborations with top cancer research hospitals in the US and Europe.
Their hybrid approach, which combines in-house R&D and international research partnerships, ensures speed, scalability, and inclusivity. Because what good is a cure if it never reaches the bedside?
Competing Against Giants — With Patients as Their True North
The oncology market is one of the most competitive in medicine, driven in part by pharmaceutical giants with billion-dollar pipelines. Start-ups often disappear in the din or get acquired before having any lasting impact.
Pallando is different. Its approach is based on a simple yet profound belief – that science must matter, access must heal, and collaboration must count. Every therapy they imagine is focused on precision — drugs that hit cancer and nothing but cancer, sparing healthy cells and reducing the brutal side effects that are a core part of most treatments. But scientific breakthroughs, scientists have learned, are not enough if they are out of people’s reach. Which is why all of Pallando’s models are designed for worldwide access, keeping life-saving treatments away from the elite markets they often settle into.
Through collaborations with world-class research facilities, Pallando accelerates the pace of innovation & validation, enabling breakthroughs to transfer rapidly from the lab to the bedside. Rather than sprint to become the biggest, Pallando is staking its spot as the most trusted biotech company that’s not about how many people we employ, but an unyielding focus on patients.
Millions in Momentum — Turning Funding Into Futures
In 2025, Pallando Therapeutics closed its first multi-million-dollar seed round, backed by international healthcare funds and biotech angels. It wasn’t just capital; it was confidence that the world is ready for a new kind of oncology company.
The funding is already having a tangible impact in the real world. Their lead therapy candidates are being developed in the clinic to bring new therapies to the patients who need them the most. At the same time, the company is expanding its research pipeline to cover a wider range of cancer types, avoiding the risk of narrowing its efforts to a particular disease area that might one day become obsolete. Just as important is the establishment of reduced-cost access programs in underserved areas, reflecting Pallando’s commitment to the fact that the future of cancer care should be accessible to all.
A Legacy in the Making — Healing With Humanity
Pallando’s story is about more than molecules, patents, or even breakthroughs—it’s about rewriting the very definition of cancer care. Their mission is to prove that the fight against cancer doesn’t have to bankrupt families, devastate patients, or remain out of reach for the many.
For the child dreaming of a future, the mother holding on to hope, or the father fighting to see another birthday—Pallando represents a lifeline of dignity and possibility.
Years from now, when survival rates rise and treatments become gentler, people will remember not just the science, but the shift—that moment when a biotech company chose compassion over exclusivity, patients over profit, and humanity over prestige.
Because the proper cure for cancer isn’t only found in a lab.
It’s found in hope, access, and trust.
And that’s precisely what Pallando Therapeutics is building—one discovery at a time.
